Search Results
Nov 06, 2025, 10:00 ET Visit Regal on November 11 to Celebrate America's Veterans with Popcorn and Movies
course of the 2023 season—just one year after their historic National Championship—the story weaves together vérité footage, intimate interviews, and rare archival material to immerse audiences in two worlds few Americans truly understand: Rugby and West Point. Non-military moviegoers
More news about: Regal
Nov 06, 2025, 09:30 ET Dublin-based Danny Cole joins Source 1 Solutions as Vice President of Managed Services, EMEA
Group. Beginning his career as a software engineer, Cole's progression from hands-on technical development to executive leadership has given him a rare, end-to-end perspective on how technology and service innovation drive business results. "Being based in Dublin keeps me close
More news about: Source 1 Solutions Inc.
Nov 06, 2025, 09:15 ET PhaseV Earns Three Prestigious Industry Awards Highlighting Leadership in AI for Clinical Development
results for more than 40 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others. Learn more at https://www.phasevtrials.com and
More news about: PhaseV
Nov 06, 2025, 09:05 ET PMI Announces "Supergoal MLS Shoe Capsule" in Partnership with Major League Soccer
From field to shelf, the lineup includes 28 MLS players, 4 rare golden figures, and an interactive unboxing experience that will be available for purchase at Walmart U.S. locations
More news about: PMI
Nov 06, 2025, 09:00 ET BorgWarner Receives R&D 100 Award for Breakthrough Electric Motor Collaboration
Laboratory's wireless power transfer capabilities, we developed a technology that matches the performance and exceeds the power density of rare earth-based motors – without using rare earth materials. This is a substantial accomplishment." The rotary transformer system wirelessly transmits
More news about: BorgWarner
Nov 06, 2025, 09:00 ET PLAYBOY ANNOUNCES WINTER ISSUE FEATURING RARE VINTAGE IMAGES OF JANE BIRKIN, 12 NEW PLAYMATES, KID CUDI, SHARON STONE AND MORE, ON STANDS NOVEMBER 11, 2025
multimedia:https://www.prnewswire.com/news-releases/playboy-announces-winter-issue-featuring-rare-vintage-images-of-jane-birkin-12-new-playmates-kid-cudi-sharon-stone-and-more-on-stands-november-11-2025-302607260.html
More news about: Playboy, Inc.
Nov 06, 2025, 09:00 ET WindRose Health Investors Named to Inc.'s Founder-Friendly Investors List
investors who offer more than just financial backing—those who bring mentorship, resources, and a true spirit of partnership to your growth journey—is both rare and invaluable," says Bonny Ghosh, editorial director at Inc. "The 2025 Founder-Friendly Investors are collaborators and dedicated to helping their
More news about: WindRose Health Investors
Nov 06, 2025, 09:00 ET NEURELIS TO PRESENT STUDY OF NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT SYMPTOMATIC CEREBRAL CAVERNOUS MALFORMATIONS (CCM), AT ANNUAL CCM MEETING
study of NRL-1049, an investigational new chemical entity Rho kinase (ROCK) inhibitor for the treatment of cerebral cavernous malformation. CCM is a rare vascular disease characterized by clusters of abnormally enlarged, thin-walled capillaries, primarily in the brain and spinal cord, that are prone to
More news about: Neurelis, Inc.
Nov 06, 2025, 08:07 ET Upway Secures $60 Million Series C to Accelerate U.S. Growth and Build the Future of Circular Mobility
sets them apart. By applying rigorous standards and advanced processes to every bike, they have built a reputation for quality and reliability that is rare in the mobility sector. Customers know they can count on Upway for a seamless, worry-free experience, no matter where they are. This commitment to trust
More news about: Upway
Nov 06, 2025, 08:00 ET Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
deficiency–related obesity, a rare genetic condition caused by disrupted MC4R signaling. Together, these programs reinforce Palatin's commitment to advancing innovative, mechanism-based obesity therapies with the potential to deliver meaningful and lasting clinical benefit across both rare and common forms of
More news about: Palatin Technologies, Inc.
Nov 06, 2025, 08:00 ET EFC Gases & Advanced Materials Announces Agreement to Join Element Solutions Inc.
semiconductor manufacturing, aerospace, and electrical infrastructure. Through continuous investment in purification, analytical capabilities, and sustainable rare gas recovery systems, EFC has become a trusted partner for companies advancing the technologies that power and connect the modern world, delivering
More news about: EFC Gases & Advanced Materials
Nov 06, 2025, 08:00 ET Cure by Deerfield Middle East Health Accelerator Selects 15 Startups for Inaugural Cohort
specializing in men's sexual and reproductive health. Arbor Bio (USA/Qatar): RNA-based therapeutics for rare diseases. Atomistic Insights (USA): AI-powered drug discovery with molecular simulations that
More news about: Cure
Nov 06, 2025, 07:30 ET FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
high fever, confusion, changes in your breathing, heart rate, and blood pressure, stiff muscles, and increased sweating; these may be symptoms of a rare but potentially fatal condition. Contact your healthcare provider or go to the emergency room if you experience signs and symptoms of NMS.
More news about: Johnson & Johnson
Nov 06, 2025, 07:27 ET MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome
for treatment of AS. Orphan Drug Designation is a status granted to support the development of investigational therapies intended for the treatment of rare diseases that affect fewer than 200,000 people in the US. This designation confers various benefits related to market exclusivity, waiver or reduction
More news about: AS2Bio
Nov 06, 2025, 07:05 ET Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential
More news about: Viking Therapeutics, Inc.
Nov 06, 2025, 07:05 ET REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for
More news about: REGENXBIO Inc.
Nov 06, 2025, 06:45 ET Core Natural Resources Reports Third Quarter 2025 Results
million to $25 million at Leer South in the fourth quarter of 2025. Potential Future Opportunity in the Rare Earth Elements and Critical Minerals Arena Core recently completed a sampling and analysis program at its
More news about: Core Natural Resources
Nov 06, 2025, 06:00 ET Golden Helix Launches VarSeq 3 and VSWarehouse 3
genomic warehousing, Golden Helix empowers customers to uncover disease-causing mutations, personalize treatment decisions, and accelerate discoveries in rare diseases and oncology. Hayley KarolTechnical Marketing SpecialistGolden Helix, Inc(406) 414- 9973
More news about: Golden Helix Inc
Nov 06, 2025, 05:00 ET GTT Group Announces Exclusive Divestiture of Pioneering AI Music Production Patent
at GTT Group. "Its early priority date and prophetic claims position it as a foundational asset in a high-growth market. We are excited to offer this rare opportunity to acquire a patent that will undoubtedly shape the future of automated sound engineering and content creation." The
More news about: Global Technology Transfer Group, Inc.
Nov 05, 2025, 23:14 ET Firsthabit Wins Dual CES 2026 Innovation Awards
This double honor is a rare achievement in the education field, demonstrating both engineering sophistication and learning effectiveness.At CES 2026, Firsthabit plans
More news about: FIRSTHABIT
Nov 05, 2025, 19:42 ET The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
hypertriglyceridemia (sHTG), including Familial Chylomicronemia Syndrome (FCS) and Multifactorial Chylomicronemia Syndrome (MCS). FCS is a rare autosomal recessive disorder caused by biallelic mutations in the Lipoprotein Lipase (LPL) gene or other key regulatory genes, with fasting TG ≥10 mmol/L
More news about: CorrectSequence Therapeutics
Nov 05, 2025, 19:00 ET The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
hypertriglyceridemia (sHTG), including Familial Chylomicronemia Syndrome (FCS) and Multifactorial Chylomicronemia Syndrome (MCS). FCS is a rare autosomal recessive disorder caused by biallelic mutations in the Lipoprotein Lipase (LPL) gene or other key regulatory genes, with fasting TG ≥10 mmol/L
More news about: CorrectSequence Therapeutics
Nov 05, 2025, 17:32 ET FAULKNER COLLISION CENTER OF LANCASTER AND MANAGER APRIL LAUSCH HONORED WITH NATIONAL I-CAR AWARDS
exceptional dedication to training, professionalism, and the advancement of complete, safe, and quality repairs. In a remarkable and rare outcome, both 2024 performance year awards were earned by the same team: Faulkner Collision Center of Lancaster and its manager, April Lausch.
More news about: I-CAR
Nov 05, 2025, 17:23 ET SCAD Students Help Recreate Atlanta's Most Haunting Cold Case for THE VANISHING
ethic. I'd recommend them to any producer." — William VanDerKloot, Director/Producer For students, the experience offered a rare window into high-stakes, real-world documentary storytelling. "We learned to balance creative choices with ethical responsibility.
More news about: Monument Motion Picture
Nov 05, 2025, 16:30 ET Tronox Reports Third Quarter 2025 Financial Results
focus by the West on diversifying away from China in rare earths presents a unique opportunity for Tronox. Our mining operations in Australia and South Africa contain substantial amounts of monazite – a rare earth mineral containing heavy and light rare earths – which can be processed for downstream use
More news about: Tronox Holdings plc